AGL 37.89 Decreased By ▼ -0.26 (-0.68%)
AIRLINK 124.10 Increased By ▲ 2.59 (2.13%)
BOP 5.67 Decreased By ▼ -0.18 (-3.08%)
CNERGY 3.75 No Change ▼ 0.00 (0%)
DCL 8.55 Increased By ▲ 0.15 (1.79%)
DFML 40.48 Decreased By ▼ -0.41 (-1%)
DGKC 87.10 Increased By ▲ 2.50 (2.96%)
FCCL 33.98 Increased By ▲ 1.28 (3.91%)
FFBL 66.01 Increased By ▲ 0.51 (0.78%)
FFL 10.20 Increased By ▲ 0.15 (1.49%)
HUBC 104.45 Increased By ▲ 0.65 (0.63%)
HUMNL 13.45 Increased By ▲ 0.20 (1.51%)
KEL 4.78 Increased By ▲ 0.35 (7.9%)
KOSM 6.84 Decreased By ▼ -0.25 (-3.53%)
MLCF 38.84 Increased By ▲ 1.34 (3.57%)
NBP 60.35 Increased By ▲ 0.10 (0.17%)
OGDC 179.65 Increased By ▲ 7.40 (4.3%)
PAEL 24.97 Increased By ▲ 0.17 (0.69%)
PIBTL 5.71 Increased By ▲ 0.01 (0.18%)
PPL 153.00 Increased By ▲ 11.31 (7.98%)
PRL 22.79 Increased By ▲ 0.07 (0.31%)
PTC 14.91 Increased By ▲ 0.17 (1.15%)
SEARL 66.85 Increased By ▲ 2.29 (3.55%)
TELE 7.01 Decreased By ▼ -0.13 (-1.82%)
TOMCL 35.70 Increased By ▲ 0.20 (0.56%)
TPLP 7.32 Increased By ▲ 0.03 (0.41%)
TREET 13.99 Decreased By ▼ -0.21 (-1.48%)
TRG 50.95 Decreased By ▼ -0.80 (-1.55%)
UNITY 26.40 Decreased By ▼ -0.20 (-0.75%)
WTL 1.23 Increased By ▲ 0.01 (0.82%)
BR100 9,717 Increased By 233.5 (2.46%)
BR30 29,237 Increased By 866.2 (3.05%)
KSE100 90,860 Increased By 1893.1 (2.13%)
KSE30 28,458 Increased By 630.4 (2.27%)

KARACHI: China will supply a coronavirus vaccine candidate developed by a unit of the China National Pharmaceutical Group (Sinopharm) to Pakistan as part of a trial agreement, the Wall Street Journal reported on Thursday. State-owned Sinopharm is set to work with the University of Karachi on vaccine trials, according to the WSJ report, which said Pakistan will receive enough doses early in distribution to vaccinate about one-fifth of its population.

The initial doses will be used to vaccinate the most vulnerable among the Pakistani population including the elderly, healthcare workers and people with medical conditions associated with serious cases of Covid-19, the report added. Earlier in April, Sinopharm had invited the National Institute of Health (NIH), Islamabad, to collaborate in conducting clinical trials of its inactivated vaccine for Covid-19 in Pakistan.

In a letter sent to NIH Executive Director Maj-Gen Dr Aamer Ikram, the general manager of China Sinopharm International Corp., Li Can, had expressed the hope that "a successful clinical trial in Pakistan will make it one of [the] first few countries for the launch of a Covid-19 vaccine".

Copyright Business Recorder, 2020

Comments

Comments are closed.